Enrigue Chacon-Cruz1, R M Rivas-Landeros2, M L Volker-Soberanes2. 1. Pediatric Infectious Diseases Service, Hospital General de Tijuana, Tijuana Baja-California, Paseo Centenario S/N, Zona Rio, Tijuana, Baja-California, ZC 22010, Mexico. 2. Microbiology Laboratory, Hospital General de Tijuana, Tijuana Baja-California, Mexico.
Abstract
BACKGROUND: In May 2012, universal vaccination with the 13-valent pneumococcal conjugate vaccine (PCV-13) was introduced for all children in the Tijuana region of Mexico, with a coverage of 80%. METHOD: Between October 2005 and September 2013 active surveillance was undertaken for all invasive pneumococcal diseases (IPDs) in children admitted to the Tijuana General Hospital. RESULTS: Following PCV-13 implementation, there was a 75% reduction in overall IPD, and no cases of serotype 19A, pneumococcal meningitis, and pneumococcal-associated deaths. CONCLUSIONS: These results are the first to show the effectiveness of PCV-13 in Mexico.
BACKGROUND: In May 2012, universal vaccination with the 13-valent pneumococcal conjugate vaccine (PCV-13) was introduced for all children in the Tijuana region of Mexico, with a coverage of 80%. METHOD: Between October 2005 and September 2013 active surveillance was undertaken for all invasive pneumococcal diseases (IPDs) in children admitted to the Tijuana General Hospital. RESULTS: Following PCV-13 implementation, there was a 75% reduction in overall IPD, and no cases of serotype 19A, pneumococcal meningitis, and pneumococcal-associated deaths. CONCLUSIONS: These results are the first to show the effectiveness of PCV-13 in Mexico.
Authors: Albert Jan van Hoek; Carmen L Sheppard; Nick J Andrews; Pauline A Waight; Mary P E Slack; Timothy G Harrison; Shamez N Ladhani; Elizabeth Miller Journal: Vaccine Date: 2014-03-21 Impact factor: 3.641
Authors: Sylvia Becker-Dreps; Erick Amaya; Lan Liu; Gilberto Moreno; Julio Rocha; Rafaela Briceño; Jorge Alemán; Michael G Hudgens; Christopher W Woods; David J Weber Journal: Pediatr Infect Dis J Date: 2014-06 Impact factor: 2.129
Authors: Enrique Chacon-Cruz; Yazbeck Velazco-Mendez; Samuel Navarro-Alvarez; Rosa M Rivas-Landeros; Maria Luisa Volker; Graciano Lopez-Espinoza Journal: J Infect Dev Ctries Date: 2012-06-15 Impact factor: 0.968
Authors: Aurora Bautista-Márquez; Vesta Richardson; Oscar Ortiz-Orozco; Maria Edilia Luna-Cruz; M Noemí Carnalla-Barajas; Gabriela Echaniz-Avilés; Miriam Bobadilla-del Valle; Lucila Martínez-Medina; Ana María Montalvo-Vázquez; Norma de la Re-Montaño; Ivette Anchondo-Martínez; Juan Carlos Tinoco-Favila; Gerardo Martínez-Aguilar; Israel Yberri-Zárate; José Antonio Girón-Hernández; José Sifuentes-Osornio; M Lourdes Guerrero; Guillermo M Ruiz-Palacios Journal: Arch Med Res Date: 2013-01-04 Impact factor: 2.235
Authors: Sheldon L Kaplan; William J Barson; Philana Ling Lin; José R Romero; John S Bradley; Tina Q Tan; Jill A Hoffman; Laurence B Givner; Edward O Mason Journal: Pediatr Infect Dis J Date: 2013-03 Impact factor: 2.129
Authors: C Hays; Q Vermee; A Agathine; A Dupuis; E Varon; C Poyart; M-C Ploy; J Raymond Journal: Eur J Clin Microbiol Infect Dis Date: 2016-12-20 Impact factor: 3.267
Authors: Enrique Chacon-Cruz; Cesar Adrian Martinez-Longoria; Eduardo Llausas-Magana; Antonio Luevanos-Velazquez; Jorge Alejandro Vazquez-Narvaez; Sandra Beltran; Ana Elena Limon-Rojas; Fernando Urtiz-Jeronimo; Jose Luis Castaneda-Narvaez; Francisco Otero-Mendoza; Fernando Aguilar-Del Real; Jesus Rodriguez-Chagoyan; Rosa Maria Rivas-Landeros; Maria Luisa Volker-Soberanes; Rosa Maria Hinojosa-Robles; Patricia Arzate-Barbosa; Laura Karina Aviles-Benitez; Fernando Ivan Elenes-Zamora; Chandra M Becka; Ricardo Ruttimann Journal: Ther Adv Vaccines Date: 2016-01-01